Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2641 to 2655 of 8916 results

  1. DB-OTO for Hearing loss [ID6728]

    Awaiting development Reference number: GID-TA11911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Bladder EpiCheck for the detection of bladder cancer recurrence (MT706)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  3. Lumella Pre-Eclampsia Test (MT687)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  4. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]

    In development Reference number: GID-TA11818 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Setrusumab for treating osteogenesis imperfecta [ID6730]

    Awaiting development Reference number: GID-TA11921 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. CM-AT for behaviours associated with autism in children and young people [ID6731]

    Awaiting development Reference number: GID-TA11955 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Artificial Intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: Early Value Assessment: draft guidance

    We are listening to your views on this Health technology evaluation. Comments close 24 February 2026.

    Health technology evaluation
    In consultation

  8. Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke

    In development Reference number: GID-IPG10439 Expected publication date: TBC

    Interventional procedures guidance
    In development

  9. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke: draft scope consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 19 February 2026.

    Interventional procedures guidance
    In consultation

  11. Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]

    In development Reference number: GID-TA10620 Expected publication date:  12 June 2026

    Technology appraisal guidance
    In development

  12. Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

    In development Reference number: GID-TA10981 Expected publication date:  08 April 2026

    Technology appraisal guidance
    In development

  13. Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

    In development Reference number: GID-TA11519 Expected publication date:  12 June 2026

    Technology appraisal guidance
    In development

  14. Artificial Intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: Early Value Assessment

    In development Reference number: GID-HTE10067 Expected publication date:  20 May 2026

    Health technology evaluations
    In development

  15. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development Reference number: GID-TA11103 Expected publication date: TBC

    Technology appraisal guidance
    In development